Suppr超能文献

单疗程大剂量地塞米松治疗优于常规泼尼松龙治疗原发性新诊断免疫性血小板减少症。

Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia.

机构信息

Genetics research center, Division of Oncology and Hematology, Department of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

出版信息

Daru. 2012 Aug 28;20(1):7. doi: 10.1186/2008-2231-20-7.

Abstract

INTRODUCTION

Immune thrombocytopenia (ITP) is an immune disorder commonly presents as isolated thrombocytopenia. Generally corticosteroids are the main treatment of ITP. This study was designed to evaluate effectiveness of high dose dexamethasone comparing conventional corticosteroid therapy in the treatment of ITP.

MATERIALS AND METHODS

In a randomized prospective study, sixty adult patients with newly diagnosed primary symptomatic ITP (Platelet count < 20,000) were evaluated. Patients divided into two groups. In group A, thirty patients (mean age of 24.9 years) received Dexamethasone 40 mg/IV/daily for four days (10 mg/q6h); and then Prednisolone 1 mg/kg/day/PO with rapid tapering of prednisolone (10 mg/week). From the other hand, in group B, thirty patients (mean age of 27.2 years) were treated with Prednisolone 1 mg/kg/day/PO for four weeks, then the drug tapered weekly.

RESULTS

All the patients in group A showed favorable response within the first seven days, 27 cases presented complete response (CR) and three cases revealed response (R). In group B, 11 cases had CR, 13 cases showed R and six cases had No response (NR). After three months, rates of CR were 80% and 23.3% in group A and B; respectively. Responses were 16.7% and 33.3%, NRs were 6.6% and 43.3% in group A and B; respectively (P < 0.0001). After 6 months, CR was 73.3% vs.16.7%, and R was 16.7% vs.36.7% and NR was 10% vs. 46.7% in group A and B; respectively (P < 0.0001). After 12 months, there was no change in response rate in group A, but in group B 53% were non responsive, 40% showed R (chronic ITP) and complete response was observed only in 6.7% (P < 0.0001). Three cases in group A and 12 cases in group B had needed splenectomy (P < 0.00002).

CONCLUSION

We showed that high dose dexamethasone is more effective than conventional steroid therapy in newly diagnosed ITP as initial treatment with less relapses and toxicities.

摘要

简介

免疫性血小板减少症(ITP)是一种常见的免疫性疾病,表现为孤立性血小板减少症。一般来说,皮质类固醇是 ITP 的主要治疗方法。本研究旨在评估大剂量地塞米松与常规皮质类固醇治疗 ITP 的疗效。

材料与方法

在一项随机前瞻性研究中,评估了 60 例新诊断的原发性有症状 ITP(血小板计数<20,000)的成年患者。患者分为两组。在 A 组中,30 例患者(平均年龄 24.9 岁)接受地塞米松 40mg/IV/天,连用 4 天(10mg/q6h);然后给予泼尼松龙 1mg/kg/天/PO,并快速减停泼尼松龙(每周 10mg)。另一方面,在 B 组中,30 例患者(平均年龄 27.2 岁)接受泼尼松龙 1mg/kg/天/PO 治疗 4 周,然后每周减药。

结果

A 组所有患者在第 7 天内均出现良好反应,27 例患者完全缓解(CR),3 例患者反应良好(R)。B 组中,11 例患者 CR,13 例患者 R,6 例患者无反应(NR)。3 个月后,A 组和 B 组的 CR 率分别为 80%和 23.3%;分别。反应率分别为 16.7%和 33.3%,NR 率分别为 6.6%和 43.3%;分别(P<0.0001)。6 个月后,CR 分别为 73.3%和 16.7%,R 分别为 16.7%和 36.7%,NR 分别为 10%和 46.7%;分别(P<0.0001)。12 个月后,A 组的反应率没有变化,但 B 组中有 53%的患者无反应,40%的患者反应良好(慢性 ITP),只有 6.7%的患者完全缓解(P<0.0001)。A 组有 3 例患者和 B 组有 12 例患者需要脾切除术(P<0.00002)。

结论

我们表明,与常规类固醇治疗相比,大剂量地塞米松作为初治新诊断的 ITP 更为有效,复发和毒性更少。

相似文献

5
[Effect of different therapeutic regimens on regulatory T cells in patients of primary immune thrombocytopenia].
Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):478-81. doi: 10.3760/cma.j.issn.0253-2727.2013.06.002.
8
Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia.
Indian J Hematol Blood Transfus. 2019 Jul;35(3):507-512. doi: 10.1007/s12288-018-1061-7. Epub 2019 Jan 1.

引用本文的文献

2
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.
Blood Adv. 2024 Mar 26;8(6):1529-1540. doi: 10.1182/bloodadvances.2023010975.
3
Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021).
Pediatr Investig. 2022 Feb 21;6(2):63-74. doi: 10.1002/ped4.12305. eCollection 2022 Jun.
4
Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.
Blood Res. 2022 Mar 31;57(1):20-28. doi: 10.5045/br.2022.2022043.
5
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern.
Res Pract Thromb Haemost. 2021 Aug 25;5(6):e12592. doi: 10.1002/rth2.12592. eCollection 2021 Aug.
6
The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis.
Front Med (Lausanne). 2021 May 25;8:656792. doi: 10.3389/fmed.2021.656792. eCollection 2021.
8
High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura.
Int J Hematol. 2020 Mar;111(3):388-395. doi: 10.1007/s12185-019-02808-6. Epub 2020 Jan 2.
9
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.

本文引用的文献

2
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura.
Haematologica. 2009 Nov;94(11):1603-7. doi: 10.3324/haematol.2009.007708. Epub 2009 Oct 1.
3
High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia.
J Clin Immunol. 2009 Sep;29(5):603-10. doi: 10.1007/s10875-009-9303-y. Epub 2009 Jun 5.
5
Immune thrombocytopenic purpura.
Indian J Pediatr. 2008 Jul;75(7):723-8. doi: 10.1007/s12098-008-0137-z. Epub 2008 Aug 21.
8
Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review.
Hum Exp Toxicol. 2006 Aug;25(8):447-52. doi: 10.1191/0960327106het647oa.
9
Treatment of immune thrombocytopenic purpura in children : current concepts.
Paediatr Drugs. 2005;7(5):325-36. doi: 10.2165/00148581-200507050-00004.
10
Corticosteroid administration depresses circulating dendritic cells in ITP patients.
Platelets. 2004 Nov;15(7):451-4. doi: 10.1080/09537100410001711497.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验